200 related articles for article (PubMed ID: 37625594)
21. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
22. Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation.
Postalcioglu M; Kim HT; Obut F; Yilmam OA; Yang J; Byun BC; Kupiec-Weglinski S; Soiffer R; Ritz J; Antin JH; Alyea E; Koreth J; Cutler C; Armand P; Paik JM; Leaf DE; Ho VT; Abdi R
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2344-2353. PubMed ID: 29758394
[TBL] [Abstract][Full Text] [Related]
23. The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy.
Sartain S; Shubert S; Wu MF; Wang T; Martinez C
Pediatr Blood Cancer; 2020 Mar; 67(3):e28070. PubMed ID: 31774252
[TBL] [Abstract][Full Text] [Related]
24. Intrapatient variability in concentration/dose ratio of tacrolimus predicts transplant-associated thrombotic microangiopathy.
Sagou K; Fukushima N; Ukai S; Goto M; Ozeki K; Kohno A
Int J Hematol; 2021 Jan; 113(1):63-72. PubMed ID: 32876853
[TBL] [Abstract][Full Text] [Related]
25. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Laskin BL; Maisel J; Goebel J; Yin HJ; Luo G; Khoury JC; Davies SM; Jodele S
Transplantation; 2013 Jul; 96(2):217-23. PubMed ID: 23698598
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
[TBL] [Abstract][Full Text] [Related]
27. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.
Schoettler ML; Carreras E; Cho B; Dandoy CE; Ho VT; Jodele S; Moissev I; Sanchez-Ortega I; Srivastava A; Atsuta Y; Carpenter P; Koreth J; Kroger N; Ljungman P; Page K; Popat U; Shaw BE; Sureda A; Soiffer R; Vasu S
Transplant Cell Ther; 2023 Mar; 29(3):151-163. PubMed ID: 36442770
[TBL] [Abstract][Full Text] [Related]
28. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation.
Qi J; Wang J; Chen J; Su J; Tang Y; Wu X; Ma X; Chen F; Ruan C; Zheng XL; Wu D; Han Y
Ann Hematol; 2017 Nov; 96(11):1849-1855. PubMed ID: 28801815
[TBL] [Abstract][Full Text] [Related]
29. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
Higham CS; Shimano KA; Melton A; Kharbanda S; Chu J; Dara J; Winestone LE; Hermiston ML; Huang JN; Dvorak CC
Pediatr Blood Cancer; 2022 May; 69(5):e29641. PubMed ID: 35253361
[TBL] [Abstract][Full Text] [Related]
30. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy.
Okamura H; Nakamae H; Shindo T; Ohtani K; Hidaka Y; Ohtsuka Y; Makuuchi Y; Kuno M; Takakuwa T; Harada N; Nishimoto M; Nakashima Y; Koh H; Hirose A; Nakamae M; Wakamiya N; Hino M; Inoue N
Front Immunol; 2021; 12():695037. PubMed ID: 34326846
[TBL] [Abstract][Full Text] [Related]
31. Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation: The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
Sala E; Neagoie AM; Lewerenz J; Saadati M; Benner A; Gantner A; Wais V; Döhner H; Bunjes D
Transplant Cell Ther; 2024 Jun; 30(6):586.e1-586.e11. PubMed ID: 38508452
[TBL] [Abstract][Full Text] [Related]
32. A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD.
Furukawa M; Wang X; Ohkawara H; Fukatsu M; Alkebsi L; Takahashi H; Harada-Shirado K; Shichishima-Nakamura A; Kimura S; Ogawa K; Ikezoe T
Blood Adv; 2019 Jul; 3(14):2128-2143. PubMed ID: 31300420
[TBL] [Abstract][Full Text] [Related]
33. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.
Shayani S; Palmer J; Stiller T; Liu X; Thomas SH; Khuu T; Parker PM; Khaled SK; Forman SJ; Nakamura R
Biol Blood Marrow Transplant; 2013 Feb; 19(2):298-304. PubMed ID: 23078784
[TBL] [Abstract][Full Text] [Related]
34. [Clinical characteristics and risk factors of pericardial effusion after hematopoietic stem cell transplantation in children with thalassemia major].
Yang CL; Wang XD; Zhou XH; Wang CJ; Zhang XL; Li Y; Yu Y; Liu SX
Zhonghua Er Ke Za Zhi; 2022 Apr; 60(4):323-328. PubMed ID: 35385938
[No Abstract] [Full Text] [Related]
35. Systematic Review of Signs and Symptoms Associated with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy.
Dandoy CE; Tsong WH; Sarikonda K; McGarvey N; Perales MA
Transplant Cell Ther; 2023 Apr; 29(4):282.e1-282.e9. PubMed ID: 36592719
[TBL] [Abstract][Full Text] [Related]
36. Late transplant-associated thrombotic microangiopathy verified in bone marrow biopsy specimens is associated with chronic GVHD and viral infections.
Hill W; Sotlar K; Hautmann A; Kolb HJ; Ullmann J; Hausmann A; Schmidt M; Tischer J; Pham TT; Rank A; Hoechstetter MA
Eur J Haematol; 2024 May; 112(5):819-831. PubMed ID: 38243840
[TBL] [Abstract][Full Text] [Related]
37. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation.
Gavriilaki E; Sakellari I; Batsis I; Mallouri D; Bousiou Z; Vardi A; Yannaki E; Constantinou V; Tsompanakou A; Vadikoliou C; Kaloyannidis P; Bamihas G; Anagnostopoulos A
Clin Transplant; 2018 Sep; 32(9):e13371. PubMed ID: 30080283
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort.
Schoettler M; Lehmann LE; Margossian S; Lee M; Kean LS; Kao PC; Ma C; Duncan CN
Blood Adv; 2020 Jun; 4(11):2536-2547. PubMed ID: 32516415
[TBL] [Abstract][Full Text] [Related]
39. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
[TBL] [Abstract][Full Text] [Related]
40. Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT.
Matsui H; Arai Y; Imoto H; Mitsuyoshi T; Tamura N; Kondo T; Kanda J; Ishikawa T; Imada K; Ueda Y; Toda Y; Anzai N; Yago K; Nohgawa M; Yonezawa A; Tsunemine H; Itoh M; Yamamoto K; Tsuji M; Moriguchi T; Takaori-Kondo A;
Blood Adv; 2020 Jul; 4(13):3169-3179. PubMed ID: 32658984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
